Business Plan

& Valuation Presentation

Contents



OUR
VISION & MISSION

Our Mission

Meridian General Hospital exists to provide safe, timely, and compassionate medical care across emergency services, surgery, diagnostics, maternity, and inpatient treatment. By integrating cardiology, pediatrics, internal medicine, orthopedics, and women's health with dedicated doctors, nurses, and support staff, the hospital aims to prevent illness through preventive screenings, empower patients with education, and guide families through follow-up care, ensuring better health outcomes for the community.

Our Vision

To be a leading regional health partner recognized for delivering high-quality, patient-centered care, advancing medical excellence through continuous learning, innovative diagnostics, and coordinated services, so that every person has timely access to transformative health experiences and improved long-term well-being.

Summary Financials Dashboard

Key performance indicators
(Base Scenario Y3)

$ 3,661k
Revenue

$ 1,648k
Gross Profit

$ 989k
EBITDA

0.00%
Target Market Share



Margins
(Stabilized by Y3)

GP Margin



EBITDA Margin



PbT Margin



Project Phases



Foundational Care | Core Expansion & | Adjacent Service | Long-Term Explorations &

Funding round is aimed to accelerate the development of Phases and create core infrastructure for operations.

Investment will be used to finance CAPEX, WC buffers, etc.

Investment $ 4,084k

Y1 CAPEX $ 4,080k | WC $ 291k

About the Company: General Overview

Meridian General Hospital stands as a comprehensive, full-service medical facility dedicated to delivering high-quality care across emergency services, surgery, diagnostics, maternity, and inpatient treatment. With a broad range of medical departments including cardiology, pediatrics, internal medicine, orthopedics, and women's health, the hospital brings together physicians, nurses, and support staff to ensure safe, timely, and coordinated care. The facility emphasizes patient-centered approaches, integrating preventive screenings, follow-up appointments, and educational programs to support ongoing wellness and early detection. Meridian General Hospital is positioned within the General Medical and Surgical Hospitals sector of Health Care and Social Assistance, focusing on a holistic continuum of care that spans acute interventions, routine health maintenance, and community outreach. The institution prioritizes evidence-based practices, state-of-the-art diagnostics, and a collaborative care model designed to improve outcomes and patient experience. By aligning clinical excellence with compassionate service, Meridian General Hospital seeks to be a trusted community health resource, delivering reliable care across diverse patient needs while maintaining strong safety standards, efficient operations, and continuous improvement across all departments.

The Main Phases: Projects & Impacts

01 Foundational Care Platform

Phase I.

Meridian General Hospital establishes a foundational offering by delivering essential emergency care, diagnostics, and inpatient services, forming a reliable, patient-centered core with streamlined workflows and safe, timely clinical outcomes.

03 Adjacent Service Extensions

Phase III

New revenue streams emerge through integrated care pathways, outpatient follow-ups, education programs, and partnerships in preventive screenings, leveraging data insights to improve efficiency and patient engagement.



02 Core Expansion & Market Growth

Phase II

The hospital expands the core with enhanced specialty services, maternity, and preventive programs, broadening access to cardiology, orthopedics, and women’s health while scaling patient volumes and reinforcing quality standards.

04 Long-Term Explorations & Disruptive Initiatives

Phase IV.

Strategic exploration targets high-impact, uncertain opportunities such as telemedicine networks, community health initiatives, and innovative care models that could redefine care delivery years ahead.

Product Impact on Core Stakeholders

Main Stakeholder	Product Benefits
Patients and Families	Individuals receiving emergency, inpatient, and preventive care, along with their caregivers and family members.
Healthcare Providers (Doctors, Nurses, Allied Health)	Clinical and support staff delivering safe and timely care, diagnostics, and follow-up services.
Hospital Leadership & Governance	Executive team and board responsible for strategy, quality, and financial sustainability.
Payers & Insurance Partners	Insurance companies and health plans coordinating coverage, reimbursements, and value-based care incentives.
Regulators & Accreditation Bodies	Government agencies and accreditation organizations ensuring compliance, safety, and reporting.
Community & Public Health Partners	Local communities, schools, and NGOs benefiting from preventive programs and outreach initiatives.
Investors & Financial Stakeholders	Interest groups providing capital and seeking sustainable returns through scalable healthcare delivery.

Sources: Company's Proprietary Assessment

Key Performance Components

Competitive Advantage

Comprehensive Care Network

Meridian General Hospital delivers integrated services—from emergency care to maternity, diagnostics, and inpatient treatment—enabled by coordinated teams across cardiology, pediatrics, orthopedics, and women's health to ensure seamless patient journeys.

Clinical Excellence & Safety

A culture of safety and timely intervention is built through interdisciplinary collaboration among doctors, nurses, and support staff, supporting high-quality outcomes and consistent adherence to evidence-based practices.

Patient-Centric Education

The hospital emphasizes preventive screenings, follow-up care, and education programs, empowering patients with knowledge to manage health proactively and engage in ongoing wellness journeys.

Marketing and Growth Strategy



Meridian General Hospital engages with local communities through health fairs, school programs, and partnerships with primary care clinics to raise awareness of preventive screenings and timely emergency care, building trust and driving patient referrals.

The hospital enhances online scheduling, telemedicine follow-ups, and virtual tours to streamline access, improve satisfaction, and capture data for personalized care journeys.

Highlight outcomes, accreditation, and multidisciplinary teams in campaigns to differentiate the hospital as a center of safe, high-quality care across cardiology, orthopedics, and women's health.

Target Groups

	Industries	Description
I	Patients in Emergency & Acute Care	Individuals seeking rapid, high-quality emergency services, diagnostics, and inpatient care with a focus on safe, timely clinical outcomes.
II	Cardiology and Chronic Disease Patients	Patients requiring cardiovascular evaluation, treatment, follow-up, and secondary prevention within integrated cardiology services.
III	Maternity and Newborn Care Seekers	Expectant families needing prenatal, delivery, and postnatal services, supported by comprehensive maternity and neonatal care.
IV	Pediatric and Family Health	Children and families needing pediatric care, preventive screenings, immunizations, and education within a child-centric hospital setting.
V	Orthopedics and Injury Care	Individuals needing orthopedic evaluation, surgery, rehabilitation, and timely follow-up for musculoskeletal injuries and conditions.
VI	Women’s Health & Gynecology	Women seeking gynecologic care, preventive screenings, and maternity-related services within integrated women’s health programs.
VII	Preventive Care & Community Outreach	Community members engaging in preventive screenings, education programs, and wellness initiatives to maintain long-term health and reduce risk factors.

Sources: Company’s Proprietary Assessment

Painpoints & Solutions

Solution from Phase I to Phase IV

	1	2	3	4	5	6	7
Painpoints	Resource Coordination during Emergencies	Diagnostic Accessibility & Throughput	Inpatient Care Continuity & Safety	Specialty Access Gaps	Maternity & Neonatal Care Strain	Preventive & Follow-Up Engagement	Data Utilization & Quality Improvement
	During high-acuity emergencies, fragmented communication and handoffs can delay Diagnosis, imaging, and treatments, risking patient safety and timely outcomes.	Limited access to timely imaging and lab results can create bottlenecks in emergency and inpatient care, prolonging length of stay for patients.	Disjointed inpatient processes and variable clinical documentation can compromise patient safety and care continuity.	Limited access to cardiology, orthopedics, and women's health specialties can delay appropriate care and affect outcomes.	Maternity services face high demand and need for coordinated obstetric and neonatal care to ensure safety and timely delivery planning.	Patients often miss follow-ups and preventive screenings, leading to missed early detection opportunities and higher readmission risk.	Underutilized data insights hinder quality improvement, performance benchmarking, and personalized patient care across departments.
Solution	Implement an integrated, real-time care coordination platform that synchronizes ER triage, diagnostics, and inpatient beds to reduce wait times and improve handoff clarity.	Deploy streamlined diagnostic workflows with rapid-result reporting, point-of-care testing, and parallel processing to accelerate decision-making.	Adopt standardized clinical pathways, unified EHR templates, and real-time clinical dashboards to ensure consistent, safe inpatient care.	Expand in-hospital specialty teams with scheduled rounds, cross-department consults, and streamlined referral processes to improve access.	Create dedicated maternity hubs with standardized obstetric pathways, neonatal readiness protocols, and continuous staffing optimization.	Implement automated follow-up scheduling, patient education portals, and reminder campaigns linked to care plans and preventive programs.	Establish a data analytics layer with dashboards, KPI tracking, and routine quality improvement cycles to drive better outcomes.

Strategic Analysis: SWOT

Strength

Comprehensive service mix across emergency, surgery, diagnostics, maternity, and inpatient care ensures broad patient appeal and referrals.

Weaknesses

High operating costs and staffing requirements create pressure on margins; dependence on specialized talent may hinder rapid scaling in labor shortages.

Opportunities

Growing demand for preventive screenings and patient education drives ancillary revenue; partnerships with insurers and community programs enhance access and referrals.

Threats

Regulatory changes and reimbursement shifts pose financial risk; intense competition from nearby hospitals; cybersecurity and data privacy threats heighten risk.

Sources: Company's Proprietary Assessment

Pestel: Analysis

P		E		S		T		E		L	
Political	8 / 10	Economic	7 / 10	Social	8 / 10	Technological	8 / 10	Environmental	6 / 10	Legal	7 / 10
Regulatory Environment: Healthcare regulations, licensing, and accreditation standards influence operations and funding.		Funding & Reimbursements: Third-party payers and insurance schemes impact revenue streams and cash flow.		Demographics & Aging: Aging population increases demand for chronic, inpatient, and emergency care.		Health IT & EMR: Electronic medical records and data exchange improve care coordination and compliance.		Facility Sustainability: Energy efficiency and waste management impact costs and regulatory compliance.		Liability & Compliance: Medical malpractice risk and ongoing compliance require robust policies.	
Public Health Policy: Government health initiatives and reimbursement policies affect service mix and volumes.		Local Economic Conditions: Economic downturns influence patient ability to access elective care and discretionary services.		Patient Experience: Shifts toward transparency, patient satisfaction, and preventive education affect service delivery.		Medical Technologies: Advances in imaging, minimally invasive surgery, and diagnostics shape capabilities.		Climate Resilience: Disaster preparedness and climate-related events affect operations and patient access.		Labor Laws: Workforce regulations influence staffing, hours, and benefits.	

Meridian General Hospital operates in a complex regulatory and reimbursement landscape; strategic emphasis on health IT, regulatory compliance, and patient-centered care is essential for sustainable growth.

Scores reflect the relative importance and potential impact of each PESTEL factor on the business

VRIO Framework: Analysis

Value	Rarity	Imitability	Organization	
Does the resource or capability enable the firm to exploit an opportunity or neutralize a threat in the environment?	Is the resource or capability controlled by only a few firms or no other firms?	Is the resource or capability costly for other firms to imitate?	Is the firm organized to exploit the resource or capability?	
Provides comprehensive, integrated healthcare services addressing urgent, chronic, and preventive needs, improving patient outcomes and hospital reputation.	Integrated service mix and multidisciplinary teams are common but high-quality execution remains relatively scarce among competitors.	Clinical capabilities and care processes are difficult to replicate quickly due to skilled workforce and established patient trust; certification and accreditation add barriers.	Structured by departments with cross-functional teams, standardized protocols, and continuous training to leverage capabilities.	Meridian General Hospital holds valuable, fairly rare, and hard-to-imitate capabilities; organized to exploit them, suggesting sustained competitive advantage in local healthcare delivery.
V	R	I	O	
Yes	Yes	Yes	Yes	Sustainable Competitive Advantage
No	No	No	No	
Competitive Disadvantage	Competitive Parity	Temporary Competitive Advantage	Unused Competitive Advantage	

Porter’s Five Forces: Analysis

Moderate: essential medical staff and suppliers; unions and credentialing influence costs.

Low to Moderate: few viable substitutes for acute and inpatient care.

High number of hospitals increases competition for patients and physicians.

Low: high capital, regulatory and accreditation barriers.



Moderate: patients have some choice but urgency limits bargaining.

In a competitive hospital market, moderate to high rivalry and regulatory barriers shape profitability, with supplier and buyer dynamics tempering margins.

High
Moderate
Low

Management Team

Overview

Overview

Overview

Overview

History & Roadmap

Jul 2028

Stage 6: research and education hub

Create residency/continuing education and clinical research programs

Jan 2028

Stage 5: inpatient care excellence

Achieve patient-safety certifications and standardized clinical pathways

Jul 2027

Stage 4: Telehealth and community programs

Launch 24/7 telemedicine access and preventive care outreach

Mar 2027

Stage 3: Diagnostic capacity upgrade

Upgrade imaging and lab capabilities with faster turnaround times

Nov 2026

Stage 2: Specialty service expansion

Introduce expanded maternity, cardiology, and orthopedics clinics.

Jul 2026

Stage 1: Digital patient flow optimization

Streamline triage and scheduling with onboarding of a EMR-linked system

Current Status .

Initial planning and stakeholder alignment in progress

Organizational and Marketing Tasks

#	Check List Item	Status	Priority	Area	ETA
General Planning and Organization					
1	Define Mission, Vision, and Value Proposition	Not Started	High	CEO	2 weeks
2	Establish Governance and Compliance Framework	Not Started	High	CFO	4 weeks
3	Develop Organizational Structure and Roles	Not Started	High	COO	3 weeks
4	Create Initial Budget and Financial Model	Not Started	High	CFO	4 weeks
5	Define Clinical Governance and Quality Standards	Not Started	High	CIO	5 weeks
6	Technology and Digital Infrastructure Assessment	Not Started	Medium	CIO	6 weeks
7	Talent Strategy and Staffing Plan (Non-HR)	Not Started	Medium	CPO	3 weeks
8	Stakeholder Engagement and Communications Plan	Not Started	Low	CMO	2 weeks
Marketing					
1	Develop the Meridian General Hospital brand positioning and messaging platform	Not Started	High	CMO	2 weeks
2	Create targeted digital marketing campaigns for emergency, maternity, cardiology, orthopedics, and women's health services	Not Started	High	CMO	4 weeks
3	Launch patient education content series (web articles, videos, and in-clinic materials) focused on preventive screenings and follow-up care	Not Started	Medium	CIO	6 weeks
4	Develop referral network strategy with local physicians and clinics to boost patient flow	Not Started	High	CRO	8 weeks
5	Implement community outreach program to raise awareness of preventive screenings and maternity services	Not Started	Medium	CBO	3 months
6	Design and launch hospital website with service directories, online appointment booking, and patient portal	Not Started	High	CIO	2 months

Overview of Phases

#	Check List Item	Status	Priority	Area	ETA
Phase 1 & Technical Set Up for next Phases					
1	Define foundational care platform governance structure	Not Started	High	CFO	Q3 2026
2	Establish emergency care, diagnostics, and inpatient service workflows	Not Started	High	COO	Q3 2026
3	Develop patient safety and quality metrics for core services	Not Started	High	CIO	Q3 2026
4	Recruit and onboard core clinical leadership for foundational services	Not Started	High	CFO	M07 2026
5	Implement core IT infrastructure and radiology/ELT integration	Not Started	High	CIO	M08 2026
6	Define intake, triage, and patient flow processes for ED and inpatient units	Not Started	High	COO	M09 2026
7	Establish initial maternity and pediatric care protocols within core platform	Not Started	Medium	CPO	M09 2026
8	Set up foundational training and patient education programs for staff	Not Started	Medium	CHRO	M10 2026
Phase 2					
1	Expand Cardiology & Orthopedics service lines into core hospital footprint	Not Started	High	CFO	M08 2026
2	Maternity ward optimization and recruitment of obstetric specialists	Not Started	High	CPO	M09 2026
3	Upgrade outpatient imaging and diagnostics throughput (MRI/CT)	Not Started	Medium	CIO	M10 2026
4	Launch preventive screening programs (cardiovascular, oncology) with integrated follow-up	Not Started	Medium	CMO	M12 2026
5	Develop women's health initiative including gynecology outreach and education	Not Started	Medium	CRO	Q1 2027
6	Implement clinical quality metrics dashboard and reporting for Phase 2	Not Started	High	CFO	Q2 2027
7	Scale inpatient capacity planning and bed management systems	Not Started	High	COO	Q2 2027
8	Establish partnerships with local primary care and specialty clinics for referral networks	Not Started	Low	CSO	Q3 2027

Overview of Phases

#	Check List Item	Status	Priority	Area	ETA
Phase 3					
1	Implement integrated care pathway pilot with outpatient follow-ups	Not Started	High	CPO	M08 2026
2	Develop data-driven patient engagement platform for preventive screenings	Not Started	High	CIO	M09 2026
3	Establish partnerships with local clinics for preventive screening referrals	Not Started	Medium	CSO	Q1 2027
4	Create outpatient follow-up clinic workflows and scheduling automation	Not Started	High	COO	M10 2026
5	Develop education program modules on preventive care with digital resources	Not Started	Medium	CMO	M09 2026
6	Launch telemedicine-enabled follow-up consultations pilot	Not Started	High	CTO	Q3 2026
7	Implement data analytics dashboard for care pathway performance	Not Started	High	CIO	Q4 2026
8	Recruit and screen care coordinators to support integrated pathways	Not Started	Medium	CFO	M12 2026
Phase 4					
1	Develop Telemedicine Network Pilot for Rural Outreach	Not Started	High	CIO	M09 2026
2	Strategic Partnerships with Community Health Organizations	Not Started	High	CFO	Q1 2027
3	Pilot Community Health Initiative with Mobile Clinics	Not Started	Medium	COO	Q3 2026
4	Advanced Data Analytics Platform for Population Health	Not Started	High	CIO	M11 2026
5	Discounted Preventive Screening Outreach Program	Not Started	Medium	CMO	M08 2027
6	Integrated Care Pathways with Tele-Consults for Post-Discharge Follow-Ups	Not Started	High	CPO	Q2 2027
7	Exploration of Alternative Care Models (Nurse Triage at Home)	Not Started	Medium	CFO	M12 2027
8	Pilot Community-Based Health Education and Wellness Programs	Not Started	Low	CLO	Q4 2027

Sources: Company's Proprietary Planning

Core Risks & Mitigation Strategies

1. Operation and maintenance risks

#	Risk Type	Area	Mitigation Strategy
1	Staffing shortages and burnout	COO	Implement scalable staffing plans and cross-training; monitor workload and adjust staffing weekly.
2	Equipment and technology downtime	CIO	Maintain preventive maintenance contracts and redundant systems; establish rapid incident response.
3	Supply chain interruptions	CFO	Diversify supplier base and maintain safety stock and alternate sourcing.
4	Facility maintenance delays	COO	Implement robust maintenance calendar and contingency plans.
5	Patient data privacy breaches	CISO	Enforce strong access controls and regular security training; incident response playbook.

2. Regulatory and legal risks

#	Risk Type	Area	Mitigation Strategy
1	Licensing and scope of practice changes	CLO	Monitor regulatory updates; maintain licensed practitioner rosters; engage with medical boards.
2	HIPAA/PHI compliance and data privacy	CIO	Implement robust data governance, encryption, and staff training on privacy.
3	Regulatory audits and reimbursement policy changes	CFO	Establish audit-ready financial controls; engage payer relations; diversify payer mix.
4	Clinical governance and patient safety standards	CPO	Maintain clinical pathways, incident reporting, and regular quality audits.
5	Medical device and pharmaceutical compliance	CIO	Vendor due diligence; inventory control; ensure device recall processes.

Core Risks & Mitigation Strategies

3. Strategic/Market Risk

#	Risk Type	Area	Mitigation Strategy
1	Market adoption and payer mix shifts	CFO	Diversify payer contracts and expand value-based care pilots
2	Competition from regional hospitals and urgent care centers	CMO	Differentiate through comprehensive services and patient experience
3	Regulatory and policy changes impacting reimbursement	CFO	Active policy monitoring and adaptive billing/compliance processes
4	Technology and data interoperability gaps	CIO	Invest in integration-ready EHR and data governance
5	Talent attraction and retention in specialized services	CHRO	Competitive compensation, career paths, and continuous training programs

4. Finance risk

#	Risk Type	Area	Mitigation Strategy
1	Cash flow volatility	CFO	Implement rolling 12-month cash flow forecasts and reserve buffers.
2	Revenue cycle risk	CFO	Strengthen revenue cycle team; automate coding and claims tracking.
3	Capital expenditure risk	CFO	Establish strict capex governance and staged investments.
4	Funding/credit availability	CFO	Diversify funding sources; maintain credit facilities with covenants.
5	Regulatory reimbursement changes	CFO	Monitor policy environments; adjust pricing and contracts proactively.

5. Other general risks

#	Risk Type	Area	Mitigation Strategy
1	Talent retention and turnover	CFO	Implement competitive compensation and career development programs.
2	Cybersecurity and data privacy	CIO	Adopt robust cyber defense, regular training, and incident response drills.
3	Reputation and patient satisfaction	CSO	Strengthen patient experience teams and rapid issue resolution.

Sources: Company's Proprietary Assessment

Market Overview (TAM, SAM and SOM)

Target Available Market (TAM)	Subindustry	$ 1,330,000,000k	Source: TAM is based on third party market estimation provided by IBIS World. CAGR is based on open source web research. Expected CAGR for industry is 7.10%
Service Available Market (SAM)	0.02%	Meridian General Hospital, with a capital base around 4.08 million, serves a substantial urban or regional market in the United States. Based on typical serviceable market reach for a single full-service hospital and conservative capacity constraints (emergency, surgery, diagnostics, maternity, and inpatient care), a realistic SAM fraction of TAM would be...	
Service Obtainable Market Y1-Y3 (SOM)	Year 1 0.60000% Year 2 0.90000% Year 3 1.20000%	With a 4,080k USD capital and a US hospital market dominated by a few large players, the first-year SOM is deliberately conservative (0.60% of SAM) to reflect limited scale. Growth in years 2 and 3 (0.90% and 1.20%) comes from targeted payer partnerships, regional referrals, and expanding core services (emergency, maternity, diagnostics) while...	

Funding Allocation

The funding will be used to finance the CAPEX and cash deficit from Year 1 operations, aiming to expedite the development process. In subsequent years the company plans to sustain operations without requiring major additional capital injection.
Table below presents the overview of expected inflows and outflows.

The total investment required is $ 4,084k

Y1 Cash Flow Stream (thnd USD)	Inflows	Outlows
Gross Profit	718	
Payroll Expenses		172
Rent & Utilities		34
Legal and Professional Fees		23
Communication Expenses		17
CAPEX		4,080
Marketing and Branding		17
Office supplies		9
Representation and Entert.		6
Training and Development		6
Other Miscellaneous		3
CAPEX & WC shortage Y1		3,649
Buffer		435
Total Required Investment (thnd USD)		4,084

Payroll Expenses
3.95%

Rent & Utilities
0.79%

Legal and Professional Fees
0.53%

Communication Expenses
0.39%

CAPEX
93.42%

Other
0.92%

Financials Dashboard

Y3 PL formation and Margins





Business Line Breakdown (thnd USD)



Revenue Formation Narrative

Meridian General Hospital targets a substantial total addressable market of 1,330,000,000k USD, with a serviceable market (SAM) representing 0 of the TAM and capturing early traction through focused payer partnerships and regional referrals. The revenue model leverages four lines of business: Emergency Care at 40, Surgical Services at 25, Diagnostics at 20, and Other at 15, distributing the mix across emergency care, surgical services, diagnostics, and other activities to optimize payer mix and utilization. In Year 1, the SOM is targeted at 1, expanding progressively to 1 in Year 2 and 1 in Year 3, translating to revenues of 1,596k USD, 2,563.974k USD, and 3,661.355k USD, respectively. This trajectory aligns with a conservative deployment of capital and scalable service delivery. With a capital base of 4,084k USD, the plan prioritizes capacity optimization, clinical excellence, and efficient patient flow to sustain margin stability while increasing outpatient and preventive care volumes. The four lines of business contribute proportional revenue shares to the total, with {Revenue_LOB_1_name} contributing {Revenue_LOB_1_percent}, {Revenue_LOB_2_name} {Revenue_LOB_2_percent}, {Revenue_LOB_3_name} {Revenue_LOB_3_percent}, and {Revenue_LOB_4_name} {Revenue_LOB_4_percent}, advancing a balanced mix that supports EBITDA resilience and reinvestment. Projected Year 1 through Year 3 revenue growth reflects continued diversification, payer negotiations, and community-focused services, enabling Meridian General Hospital to capture incremental share within the 1,330,000,000k USD market while maintaining capital discipline and high-quality patient outcomes.

$ 3,661k Y3 Projected Revenue

0.00% Market Share



Revenue Calculation Details

Revenue Formation	M1	M2	M3	M4	M5	M6	M7	M8	M9	M10	M11	M12	Y1	Y2	Y3
Emergency Care	*40.00%*	*40.00%*	*40.00%*	*40.00%*	*40.00%*	*40.00%*	*40.00%*	*40.00%*	*40.00%*	*40.00%*	*40.00%*	*40.00%*	*40.00%*	*40.00%*	*40.00%*
Surgical Services	*25.00%*	*25.00%*	*25.00%*	*25.00%*	*25.00%*	*25.00%*	*25.00%*	*25.00%*	*25.00%*	*25.00%*	*25.00%*	*25.00%*	*25.00%*	*25.00%*	*25.00%*
Diagnostics	*20.00%*	*20.00%*	*20.00%*	*20.00%*	*20.00%*	*20.00%*	*20.00%*	*20.00%*	*20.00%*	*20.00%*	*20.00%*	*20.00%*	*20.00%*	*20.00%*	*20.00%*
Other	*15.00%*	*15.00%*	*15.00%*	*15.00%*	*15.00%*	*15.00%*	*15.00%*	*15.00%*	*15.00%*	*15.00%*	*15.00%*	*15.00%*	*15.00%*	*15.00%*	*15.00%*

Emergency Care	40	40	40	48	48	48	59	59	59	67	67	67	638	1,026	1,465
Surgical Services	25	25	25	30	30	30	37	37	37	42	42	42	399	641	915
Diagnostics	20	20	20	24	24	24	29	29	29	33	33	33	319	513	732
Other	15	15	15	18	18	18	22	22	22	25	25	25	239	385	549
Total Revenue (thnd USD)	100	100	100	120	120	120	146	146	146	166	166	166	1,596	2,564	3,661

Total revenue is expected to reach $ 3,661k by year 3.

Main revenue driver are:

- Emergency Care which generates $ 1,465k by Year 3
- Surgical Services which generates $ 915k by Year 3

Expected CAGR for total Revenue in Y1-Y3 is 51.46 %



COGS Calculation Details

COGS Formation	M1	M2	M3	M4	M5	M6	M7	M8	M9	M10	M11	M12	Y1	Y2	Y3
Labor Costs	28.00%	28.00%	28.00%	28.00%	28.00%	28.00%	28.00%	28.00%	28.00%	28.00%	28.00%	28.00%	28.00%	28.00%	28.00%
Medical Supplies	14.00%	14.00%	14.00%	14.00%	14.00%	14.00%	14.00%	14.00%	14.00%	14.00%	14.00%	14.00%	14.00%	14.00%	14.00%
Diagnostics & Tests	9.00%	9.00%	9.00%	9.00%	9.00%	9.00%	9.00%	9.00%	9.00%	9.00%	9.00%	9.00%	9.00%	9.00%	9.00%
Other	4.00%	4.00%	4.00%	4.00%	4.00%	4.00%	4.00%	4.00%	4.00%	4.00%	4.00%	4.00%	4.00%	4.00%	4.00%
Labor Costs	28	28	28	34	34	34	41	41	41	47	47	47	447	718	1,025
Medical Supplies	14	14	14	17	17	17	20	20	20	23	23	23	223	359	513
Diagnostics & Tests	9	9	9	11	11	11	13	13	13	15	15	15	144	231	330
Other	4	4	4	5	5	5	6	6	6	7	7	7	64	103	146
Total COGS (thnd USD)	55	55	55	66	66	66	80	80	80	91	91	91	878	1,410	2,014

Total COGS is expected to reach '$ 2,014k by year 3.

Main revenue driver are:

• Labor Costs which generates $ 1,025k by Year 3

• Medical Supplies which generates $ 513k by Year 3

Expected CAGR for total COGS in Y1-Y3 is 51.46 %



SG&A Calculation Details

OPEX Formation	M1	M2	M3	M4	M5	M6	M7	M8	M9	M10	M11	M12	Y1	Y2	Y3
Payroll Expenses	*10.80%*	*10.80%*	*10.80%*	*10.80%*	*10.80%*	*10.80%*	*10.80%*	*10.80%*	*10.80%*	*10.80%*	*10.80%*	*10.80%*	*10.80%*	*10.80%*	*10.80%*
Rent & Utilities	*2.16%*	*2.16%*	*2.16%*	*2.16%*	*2.16%*	*2.16%*	*2.16%*	*2.16%*	*2.16%*	*2.16%*	*2.16%*	*2.16%*	*2.16%*	*2.16%*	*2.16%*
Communication Expenses	*1.08%*	*1.08%*	*1.08%*	*1.08%*	*1.08%*	*1.08%*	*1.08%*	*1.08%*	*1.08%*	*1.08%*	*1.08%*	*1.08%*	*1.08%*	*1.08%*	*1.08%*
Office supplies	*0.54%*	*0.54%*	*0.54%*	*0.54%*	*0.54%*	*0.54%*	*0.54%*	*0.54%*	*0.54%*	*0.54%*	*0.54%*	*0.54%*	*0.54%*	*0.54%*	*0.54%*
Legal and Professional Fees	*1.44%*	*1.44%*	*1.44%*	*1.44%*	*1.44%*	*1.44%*	*1.44%*	*1.44%*	*1.44%*	*1.44%*	*1.44%*	*1.44%*	*1.44%*	*1.44%*	*1.44%*
Marketing and Branding	*1.08%*	*1.08%*	*1.08%*	*1.08%*	*1.08%*	*1.08%*	*1.08%*	*1.08%*	*1.08%*	*1.08%*	*1.08%*	*1.08%*	*1.08%*	*1.08%*	*1.08%*
Representation and Entertainment	*0.36%*	*0.36%*	*0.36%*	*0.36%*	*0.36%*	*0.36%*	*0.36%*	*0.36%*	*0.36%*	*0.36%*	*0.36%*	*0.36%*	*0.36%*	*0.36%*	*0.36%*
Training and Development	*0.36%*	*0.36%*	*0.36%*	*0.36%*	*0.36%*	*0.36%*	*0.36%*	*0.36%*	*0.36%*	*0.36%*	*0.36%*	*0.36%*	*0.36%*	*0.36%*	*0.36%*
Other Miscellaneous	*0.18%*	*0.18%*	*0.18%*	*0.18%*	*0.18%*	*0.18%*	*0.18%*	*0.18%*	*0.18%*	*0.18%*	*0.18%*	*0.18%*	*0.18%*	*0.18%*	*0.18%*
Payroll Expenses	11	11	11	13	13	13	16	16	16	18	18	18	172	277	395
Rent & Utilities	2	2	2	3	3	3	3	3	3	4	4	4	34	55	79
Communication Expenses	1	1	1	1	1	1	2	2	2	2	2	2	17	28	40
Office supplies	1	1	1	1	1	1	1	1	1	1	1	1	9	14	20
Legal and Professional Fees	1	1	1	2	2	2	2	2	2	2	2	2	23	37	53
Marketing and Branding	1	1	1	1	1	1	2	2	2	2	2	2	17	28	40
Representation and Entertainment	0	0	0	0	0	0	1	1	1	1	1	1	6	9	13
Training and Development	0	0	0	0	0	0	1	1	1	1	1	1	6	9	13
Other Miscellaneous	0	0	0	0	0	0	0	0	0	0	0	0	3	5	7
Total SG&A (thnd USD)	18	18	18	22	22	22	26	26	26	30	30	30	287	462	659

PaT Expectations

Income Statement (thnd USD)	M1	M2	M3	M4	M5	M6	M7	M8	M9	M10	M11	M12	Y1	Y2	Y3
Revenue	**100**	**100**	**100**	**120**	**120**	**120**	**146**	**146**	**146**	**166**	**166**	**166**	**1,596**	**2,564**	**3,661**
Emergency Care	40	40	40	48	48	48	59	59	59	67	67	67	638	1,026	1,465
Surgical Services	25	25	25	30	30	30	37	37	37	42	42	42	399	641	915
Diagnostics	20	20	20	24	24	24	29	29	29	33	33	33	319	513	732
Other	15	15	15	18	18	18	22	22	22	25	25	25	239	385	549
COGS	**-55**	**-55**	**-55**	**-66**	**-66**	**-66**	**-80**	**-80**	**-80**	**-91**	**-91**	**-91**	**-878**	**-1,410**	**-2,014**
Labor Costs	-28	-28	-28	-34	-34	-34	-41	-41	-41	-47	-47	-47	-447	-718	-1,025
Medical Supplies	-14	-14	-14	-17	-17	-17	-20	-20	-20	-23	-23	-23	-223	-359	-513
Diagnostics & Tests	-9	-9	-9	-11	-11	-11	-13	-13	-13	-15	-15	-15	-144	-231	-330
Other	-4	-4	-4	-5	-5	-5	-6	-6	-6	-7	-7	-7	-64	-103	-146
Gross Profit	45	45	45	54	54	54	66	66	66	75	75	75	718	1,154	1,648
SG&A Personal Expenses	-11	-11	-11	-13	-13	-13	-16	-16	-16	-18	-18	-18	-172	-277	-395
SG&A Operating Expenses	-7	-7	-7	-9	-9	-9	-11	-11	-11	-12	-12	-12	-115	-185	-264
EBITDA	27	27	27	32	32	32	40	40	40	45	45	45	431	692	989
Depreciation	-31	-31	-31	-31	-31	-31	-31	-31	-31	-31	-31	-31	-377	-377	-377
EBIT	-5	-5	-5	1	1	1	8	8	8	13	13	13	53	315	611
Interest Expense	-2	-2	-2	-2	-2	-2	-2	-2	-2	-2	-2	-2	-20	-20	-20
Profit before Tax	-6	-6	-6	-1	-1	-1	6	6	6	12	12	12	33	295	591
Tax	2	2	2	0	0	0	-2	-2	-2	-3	-3	-3	-9	-77	-154
Profit after Tax (thnd USD)	-5	-5	-5	-1	-1	-1	5	5	5	9	9	9	25	218	437

Sources: Company's Proprietary Planning

Balance Sheet Statement

Balance Sheet (thnd USD)	M1	M2	M3	M4	M5	M6	M7	M8	M9	M10	M11	M12	Y1	Y2	Y3
Cash & Cash Equivalents	164	189	202	214	245	260	272	310	336	360	403	450	450	976	1,668
Accounts Receivable	100	100	100	120	120	120	146	146	146	166	166	166	166	267	381
Inventory	55	55	66	66	66	80	80	80	91	91	91	88	88	126	210
Prepaid Expenses	4	4	4	4	4	5	5	5	6	6	6	6	6	8	14
Deferred Tax Assets	2	3	5	5	5	5	4	2	0	-	-	-	-	-	-
Current Assets	323	350	377	409	440	470	508	544	580	623	667	710	710	1,377	2,273
Medical imaging and diagnostic equipment	1,186	1,171	1,157	1,143	1,129	1,114	1,100	1,086	1,071	1,057	1,043	1,029	1,029	857	686
Hospital infrastructure and facilities modernization	1,496	1,492	1,488	1,483	1,479	1,475	1,471	1,467	1,463	1,458	1,454	1,450	1,450	1,400	1,350
Clinical and patient care equipment (surgical, acute care, monitoring)	895	890	885	880	875	870	865	860	855	850	845	840	840	780	720
Information technology and cybersecurity systems	472	464	456	448	440	432	424	416	408	400	392	384	384	288	192
Non-Current Assets	4,049	4,017	3,986	3,954	3,923	3,891	3,860	3,828	3,797	3,765	3,734	3,703	3,703	3,325	2,948
Total Assets	4,372	4,367	4,363	4,363	4,362	4,362	4,367	4,372	4,377	4,389	4,401	4,412	4,412	4,702	5,221
Accounts Payable	4	4	4	4	4	4	5	5	5	6	6	6	6	10	14
Short-Term Loans	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued Interest Expenses	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
Deferred Tax Liabilities	-	-	-	-	-	-	-	-	-	3	6	9	9	77	154
Current Liabilities	5	5	5	6	6	6	7	7	7	10	13	16	16	88	169
Loans and Other Borrowings	287	287	287	287	287	287	287	287	287	287	287	287	287	287	287
Non-Current Liabilities	287	287	287	287	287	287	287	287	287	287	287	287	287	287	287
Total Liabilities	293	293	293	293	293	293	294	294	294	298	301	304	304	375	456
Paid-In Capital	4,084	4,084	4,084	4,084	4,084	4,084	4,084	4,084	4,084	4,084	4,084	4,084	4,084	4,084	4,084
Retained Earnings	-	-	-	-	-	-	-	-	-	-	-	-	-	25	243
Current Period Earnings	-5	-9	-14	-14	-15	-16	-11	-6	-1	7	16	25	25	218	437
Total Equity	4,079	4,075	4,070	4,070	4,069	4,068	4,073	4,078	4,083	4,091	4,100	4,109	4,109	4,327	4,764

Cash Flow Statement - Direct

Cash Flow Statement - Direct (thnd USD)	M1	M2	M3	M4	M5	M6	M7	M8	M9	M10	M11	M12	Y1	Y2	Y3
Initial Balance	233	164	189	202	214	245	260	272	310	336	360	403	-	450	976
Cash from Sales of Goods / Services	-	100	100	100	120	120	120	146	146	146	166	166	1,430	2,463	3,547
Payments to Employees / Vendors	-69	-73	-84	-87	-87	-102	-106	-107	-118	-121	-121	-118	-1,247	-1,906	-2,753
Advances Paid / Received	-	-	-1	-	-	-1	-	-	-1	-	-	0	-6	-2	-5
Taxes Paid	-	-	-	-	-	-	-	-	-	-	-	-	-	-9	-77
Interest Paid	-	-2	-2	-2	-2	-2	-2	-2	-2	-2	-2	-2	-18	-20	-20
CF from Operating Activities	-69	25	14	11	31	15	12	38	26	24	43	47	158	526	692
Acquisition of															
Medical imaging and diagnostic equipment	-	-	-	-	-	-	-	-	-	-	-	-	-1,200	-	-
Hospital infrastructure and facilities modernization	-	-	-	-	-	-	-	-	-	-	-	-	-1,500	-	-
Clinical and patient care equipment (surgical, acute care, monitoring)	-	-	-	-	-	-	-	-	-	-	-	-	-900	-	-
Information technology and cybersecurity systems	-	-	-	-	-	-	-	-	-	-	-	-	-480	-	-
CF from Investing Activities	-	-	-	-	-	-	-	-	-	-	-	-	-4,080	-	-
Loans Received / Paid	-	-	-	-	-	-	-	-	-	-	-	-	287	-	-
Investments Received / Paid	-	-	-	-	-	-	-	-	-	-	-	-	4,084	-	-
CF from Financing Activities	-	-	-	-	-	-	-	-	-	-	-	-	4,371	-	-
Ending Balance	164	189	202	214	245	260	272	310	336	360	403	450	450	976	1,668

Assumptions:

- invoices are paid in 30 days;
- inventory is built for the next month;
- salaries are paid in the same month;
- half of admin expenses except salaries is prepaid;
- half of admin expenses except salaries is paid in 30 days;
- interest expenses are paid in the next month.

Cash Flow Statement - Indirect

Cash Flow Statement - Indirect (thnd USD)	M1	M2	M3	M4	M5	M6	M7	M8	M9	M10	M11	M12	Y1	Y2	Y3
Initial Balance	233	164	189	202	214	245	260	272	310	336	360	403	-	450	976
EBIT	-5	-5	-5	1	1	1	8	8	8	13	13	13	53	315	611
Δ Receivables & Prepaids	-100	-	-1	-20	-	-1	-27	-	-1	-20	-	0	-172	-103	-120
Δ Payables	4	-	-	1	-	-	1	-	-	1	-	-	6	4	4
Δ Inventory	-	-	-11	-	-	-15	-	-	-11	-	-	3	-88	-38	-84
Δ Depreciation	31	31	31	31	31	31	31	31	31	31	31	31	377	377	377
Tax Paid	-	-	-	-	-	-	-	-	-	-	-	-	-	-9	-77
Interest Expenses	-	-2	-2	-2	-2	-2	-2	-2	-2	-2	-2	-2	-18	-20	-20
CF from Operating Activities	-69	25	14	11	31	15	12	38	26	24	43	47	158	526	692
Acquisition of															
Medical imaging and diagnostic equipment	-	-	-	-	-	-	-	-	-	-	-	-	-1,200	-	-
Hospital infrastructure and facilities modernization	-	-	-	-	-	-	-	-	-	-	-	-	-1,500	-	-
Clinical and patient care equipment (surgical, acute care, monitoring)	-	-	-	-	-	-	-	-	-	-	-	-	-900	-	-
Information technology and cybersecurity systems	-	-	-	-	-	-	-	-	-	-	-	-	-480	-	-
CF from Investing Activities	-	-	-	-	-	-	-	-	-	-	-	-	-4,080	-	-
Loans Received / Paid	-	-	-	-	-	-	-	-	-	-	-	-	287	-	-
Investments Received / Paid	-	-	-	-	-	-	-	-	-	-	-	-	4,084	-	-
CF from Financing Activities	-	-	-	-	-	-	-	-	-	-	-	-	4,371	-	-
Ending Balance	164	189	202	214	245	260	272	310	336	360	403	450	450	976	1,668

Assumptions:

- invoices are paid in 30 days;
- inventory is built for the next month;
- salaries are paid in the same month;
- half of admin expenses except salaries is prepaid;
- half of admin expenses except salaries is paid in 30 days;
- interest expenses are paid in the next month.

Cost of Capital Estimation

Required Return on Equity Derivation

- 1. RE 11.75%
  - 2. RF 4.29%
    - 2.1. TSY Bond 4.64%
    - 2.2. Country Risk 0.35%
  - 3. Adj ERP 3.46%
    - 3.1. ERP 4.58%
      - 3.1.1. Mature market ERP 4.23%
      - 3.1.2. Country Risk 0.35%
        - 3.1.2.1. Rating-based Default 0.23%
        - 3.1.2.2. Default Spread Multiple 1.52
    - 3.2. Total levered β 0.75
      - 3.2.1. Tax rate 26.00% and D/E Ratio 0.47
      - 3.2.2. Unlevered β 0.56
  - 4. Illiquidity Discount 4.00%

Sources: Aswath Damodaran, web search

Cost of Capital: CAPM Inputs

Methodology

Weighted Average Cost of Capital is calculated using Capital Asset Pricing Model (CAPM). Since the company is purely equity funded the WACC is equal to its Required Return on Equity R(E). The main research inputs used in calculations are based on studies published by professor at Stern School of Business Aswath Damodaran. Return on Equity R(E) is R(E)=R(F)+β ∗ (ERP), where: R(F) is Risk Free Rate. The basis for calculation of R(F) is the average of the yield of USD 30 Year TSY Bond. The horizon. ERP is Mature Market Equity Risk Premium. It incorporates market estimates for Rating-Based Default Spread and Default Spread Multiple (β) is average equity betas of correspondingindustries. Despite the company has no debt, the unlevered beta was levered with industry average figures to reflect the long-term D/E ration in the capital structure. Additionally, Illiquidity Risk Premiumof 4% is added to the estimated Return on Equity to reflect risk associated with firm being Privately Held vs Publicly Traded Companies.

Additional Assumptions

To calculate the companies Firm Value, its future Free Cash Flow to Equity (FCFE) is discounted using estimated Required Return on Equity.

The 3rd-year projected cash flow is used as a representation of the long-term Free Cash Flow to the Equity (FCFE). This approach may understate the valuation because cash flows are expected to grow more aggressively in the first 10 years, and the growth from years 4 to 10 is not reflected in this calculation. Long-term growth rate of 5% is applied.

After discounting the cashflows and measuring the Firm Value it is adjusted to historical estimate of Start-up firm's survival rate. The allows to incorporate risk of start-ups fails.

Survival of new establishments

	Proportion of firms that were started in 1998 that survived through						
	Year 1	*Year 2*	*Year 3*	*Year 4*	*Year 5*	*Year 6*	*Year 7*
Natural resources	82.33%	69.54%	59.41%	49.56%	43.43%	39.96%	36.68%
Construction	80.69%	65.73%	53.56%	42.59%	36.96%	33.36%	29.96%
Manufacturing	84.19%	68.67%	56.98%	47.41%	40.88%	37.03%	33.91%
Transportation	82.58%	66.82%	54.70%	46.68%	38.21%	34.12%	31.02%
Information	80.75%	62.85%	49.49%	37.70%	31.24%	28.29%	24.78%
Financial activities	84.09%	69.57%	58.56%	49.24%	43.93%	40.34%	36.90%
Business services	82.32%	66.82%	55.13%	44.28%	38.11%	34.46%	31.08%
Health services	85.59%	72.83%	63.73%	55.37%	50.09%	46.47%	43.71%
Leisure	81.15%	64.99%	53.61%	43.76%	38.11%	34.54%	31.40%
Other services	80.72%	64.81%	53.32%	43.88%	37.05%	32.33%	28.77%
All firms	81.24%	65.77%	54.29%	44.36%	38.29%	34.44%	31.18%

http://pages.stern.nyu.edu/~adamodar/New_Home_Page/datafile/ctryprem.html   https://pages.stern.nyu.edu/~adamodar/pdfiles/papers/younggrowth.pdf   http://pages.stern.nyu.edu/~adamodar/

Business Valuation

DCF	(thnd USD)	Y1	Y2	Y3	Y4	Y5	Y6	Y7
	Profit after Tax	**25**	**218**	**437**	**469**	**502**	**537**	**576**
	Growth% Y4-Y7				7.10%	7.10%	7.10%	7.10%
	Growth% Y7	3.50%						
	WACC'	**11.75%**						
	PV Y1-Y7 at Y0	22	175	313	300	288	276	265
	PV Y7 --> Y0	3,320						
	NPV (thnd USD)	4,959						

Assumed 3Y Survival Rate	50%

Final Valuation	$ 2,479k

The valuation is conducted using the Discounted Cash Flow (DCF) method. In this method, the projected cash flows for a period of 7 years, along with a terminal value, are discounted at a rate of 11.75 % to determine the Firm Value.

Starting from year 3 onwards, the cash flows are estimated to grow at a rate of 7.10 %, which is consistent with the market Compound Annual Growth Rate (CAGR) trend. Beyond year 7, the cash flows are assumed to grow at a long-term growth rate of 3.50 %.

To account for the inherent risks associated with a start-up venture, the Firm Value is adjusted using the historical survival rate of newly established firms. As indicated by the study conducted by Aswath Damodaran, there was approximately 50% probability of survival for Information sector companies. Taking into account the project's current stage of development and risk profile, the final survival rate has been assumed at 50%. This adjustment allows to incorporate the risk profile of the business and provide a more comprehensive assessment of its value.

It is important to note that if the company can successfully navigate through its initial three years of operation, it is expected to have a significantly higher likelihood of becoming a going concern. This underscores the importance of demonstrating resilience and establishing a solid foundation during the critical early stages of the business.

Sources: Company's Proprietary Planning

Scenario Analysis: Narrative

Scenario analysis explores how external and internal factors influence key assumptions in financial planning. By analyzing potential positive and negative outcomes, company can better anticipate risks and opportunities when evaluating their future cash flows and overall valuation.

KPI	Scenario	Narrative	KPI affected by
Revenue	Positive	This scenario reflects a favorable market environment or a strategic breakthrough, leading to higher projected revenue. It showcases the potential rewards of scaling and innovative approaches.	higher by 15%
	Negative	This scenario accounts for challenging conditions such as economic downturns or market disruptions, forecasting a potential revenue decrease. It emphasizes the importance of adaptability and risk management.	lower by 15%
COGS	Positive	This scenario demonstrates the benefits of operational efficiency or cost-saving strategies, resulting in reduced COGS. It highlights the value of innovation in supply chain and operations.	lower by 20%
	Negative	This scenario addresses rising costs due to external pressures, resulting in an increase in COGS. It underlines the need for proactive cost-control measures.	higher by 20%
Discount Ra te (RoE)	Positive	This scenario assumes a decrease in the discount rate (RoE) due to improved market conditions, lower perceived risk, or favorable macroeconomic factors. A lower discount rate increases the present value of future cash flows, enhancing the...	lower by 10%
		This scenario models an increase in the discount rate (RoE) driven by higher market risk, macroeconomic instability, or industry-	

Scenario Analysis: Results

Scenario analysis explores how external and internal factors influence key assumptions in financial planning. By analyzing potential positive and negative outcomes, company can better anticipate risks and opportunities when evaluating their future cash flows and overall valuation.

Scenario Analysis			Revenue		COGS		Discount Rate	
	KPIs	Base	Positive	Negative	Positive	Negative	Positive	Negative
Input	Revenue	no impact	15%	-15%	no impact	no impact	no impact	no impact
	COGS	no impact	no impact	no impact	-20%	20%	no impact	no impact
	RoE	no impact	no impact	no impact	no impact	no impact	-10%	10%
Output	Revenue Y3	$ 3,661k	$ 4,211k	$ 3,112k	$ 3,661k	$ 3,661k	$ 3,661k	$ 3,661k
	Gross Profit Y3	$ 1,648k	$ 1,895k	$ 1,400k	$ 2,050k	$ 1,245k	$ 1,648k	$ 1,648k
	GP Margin	45%	45%	45%	56%	34%	45%	45%
	EBITDA Y3	$ 989k	$ 1,137k	$ 840k	$ 1,391k	$ 586k	$ 989k	$ 989k
	EBITDA Margin	27%	27%	27%	38%	16%	27%	27%
	Net Profit Y3	$ 437k	$ 547k	$ 328k	$ 735k	$ 139k	$ 437k	$ 437k
	Profit Margin	12%	13%	11%	20%	4%	12%	12%
	Final Valuation	$ 2,479k	$ 3,129k	$ 1,830k	$ 4,243k	$ 716k	$ 2,944k	$ 2,132k

Sources: Company's Proprietary Information

Stress Test: Growth Under Pressure

Stress tests provide a comprehensive view of how businesses might perform under extreme conditions, enabling better preparation for the uncertainties of challenges.

Scenario Name

Growth Under Pressure

Story

This scenario explores the challenges of managing rapid growth while dealing with operational bottlenecks. A surge in demand and revenue places significant strain on supply chains and internal processes. Despite achieving higher sales volumes, inefficiencies in scaling lead to increased costs and a heightened risk perception, keeping the discount rate elevated. 'Growth Under Pressure' examines how businesses can balance seizing growth opportunities while investing in infrastructure, talent, and systems to support scalability.

KPIs impact

Revenue Higher by 20%	**COGS** Higher by 30%
OPEX Higher by 40%	**Discount Rate** unaffected

Results



-$ 1,215k
Valuation

$ 4,394k
Revenue Y3

$ 145k
EBITDA

-$ 187k
Profit After Tax



Gross Profit Margin Y3

EBITDA Margin Y3



Stress Test: The Perfect Storm

Stress tests provide a comprehensive view of how businesses might perform under extreme conditions, enabling better preparation for the uncertainties of challenges.

Scenario Name

The Perfect Storm

Story

This scenario simulates the convergence of adverse market conditions and rising operational challenges. A sharp downturn in market demand coincides with increased costs due to inflation and supply chain disruptions. The combination results in a dual hit to both top-line revenue and operational margins. Additionally, external factors such as economic instability elevate the discount rate, amplifying the pressure on future cash flows. Businesses facing 'The Perfect Storm' must focus on resilience through diversified revenue streams, cost-control measures, and contingency planning.

KPIs impact

Revenue
Lower by 10%

COGS
Higher by 25%

OPEX
Higher by 30%

Discount Rate
Higher by 10%

Results



-$ 634k
Valuation

$ 3,295k
Revenue Y3

$ 259k
EBITDA

-$ 103k
Profit After Tax



Gross Profit Margin Y3

EBITDA Margin Y3



Sensitivity Analysis: SAM & SOM

This sensitivity analysis evaluates the potential impact of changes in Serviceable Addressable Market (SAM) and Serviceable Obtainable Market (SOM) on key financial metrics. By simulating percentage variations in SAM and SOM, this analysis helps identify how shifts in market assumptions affect revenue, profitability, and overall valuation.

		SAM						SOM					
		-20%	-10%	-5%	5%	10%	20%	-9%	-6%	-3%	3%	6%	9%
Revenue	Y1	$ 1,277k	$ 1,436k	$ 1,516k	$ 1,676k	$ 1,756k	$ 1,915k	$ 1,452k	$ 1,500k	$ 1,548k	$ 1,644k	$ 1,692k	$ 1,740k
	Y2	$ 2,051k	$ 2,308k	$ 2,436k	$ 2,692k	$ 2,820k	$ 3,077k	$ 2,333k	$ 2,410k	$ 2,487k	$ 2,641k	$ 2,718k	$ 2,795k
	Y3	$ 2,929k	$ 3,295k	$ 3,478k	$ 3,844k	$ 4,027k	$ 4,394k	$ 3,332k	$ 3,442k	$ 3,552k	$ 3,771k	$ 3,881k	$ 3,991k
Gross Profit	Y1	$ 575k	$ 646k	$ 682k	$ 754k	$ 790k	$ 862k	$ 654k	$ 675k	$ 697k	$ 740k	$ 761k	$ 783k
	Y2	$ 923k	$ 1,038k	$ 1,096k	$ 1,211k	$ 1,269k	$ 1,385k	$ 1,050k	$ 1,085k	$ 1,119k	$ 1,188k	$ 1,223k	$ 1,258k
	Y3	$ 1,318k	$ 1,483k	$ 1,565k	$ 1,730k	$ 1,812k	$ 1,977k	$ 1,499k	$ 1,549k	$ 1,598k	$ 1,697k	$ 1,746k	$ 1,796k
GP Margin	Y1	45%	45%	45%	45%	45%	45%	45%	45%	45%	45%	45%	45%
	Y2	45%	45%	45%	45%	45%	45%	45%	45%	45%	45%	45%	45%
	Y3	45%	45%	45%	45%	45%	45%	45%	45%	45%	45%	45%	45%
EBITDA	Y1	$ 345k	$ 388k	$ 409k	$ 452k	$ 474k	$ 517k	$ 392k	$ 405k	$ 418k	$ 444k	$ 457k	$ 470k
	Y2	$ 554k	$ 623k	$ 658k	$ 727k	$ 762k	$ 831k	$ 630k	$ 651k	$ 672k	$ 713k	$ 734k	$ 755k
	Y3	$ 791k	$ 890k	$ 939k	$ 1,038k	$ 1,087k	$ 1,186k	$ 900k	$ 929k	$ 959k	$ 1,018k	$ 1,048k	$ 1,078k
EBITDA Margin	Y1	27%	27%	27%	27%	27%	27%	27%	27%	27%	27%	27%	27%
	Y2	27%	27%	27%	27%	27%	27%	27%	27%	27%	27%	27%	27%
	Y3	27%	27%	27%	27%	27%	27%	27%	27%	27%	27%	27%	27%
Net Profit	Y1	-$ 39k	-$ 7k	$ 9k	$ 41k	$ 57k	$ 89k	-$ 4k	$ 6k	$ 15k	$ 34k	$ 44k	$ 53k
	Y2	$ 116k	$ 167k	$ 193k	$ 244k	$ 269k	$ 321k	$ 172k	$ 187k	$ 203k	$ 234k	$ 249k	$ 264k
	Y3	$ 291k	$ 364k	$ 401k	$ 474k	$ 511k	$ 584k	$ 372k	$ 394k	$ 416k	$ 459k	$ 481k	$ 503k
Profit Margin	Y1	-3%	-0%	1%	2%	3%	5%	-0%	0%	1%	2%	3%	3%
	Y2	6%	7%	8%	9%	10%	10%	7%	8%	8%	9%	9%	9%
	Y3	10%	11%	12%	12%	13%	13%	11%	11%	12%	12%	12%	13%
Final Valuation		$ 1,614k	$ 2,046k	$ 2,263k	$ 2,696k	$ 2,912k	$ 3,345k	$ 2,090k	$ 2,220k	$ 2,350k	$ 2,609k	$ 2,739k	$ 2,869k

Glossary

Abbreviations

Adj - Adjusted
Admin - Administrative Expense
Av - Average
b - Billions of
B2B - Business to Business
B2C - Business to Customer
C-level - Chief level
CAGR - Compounded Annual Growth Rate
CAPEX - Capital Expenditure
CAPM - Capital Asset Pricing Model
CBDO - Chief Business Development Officer
CEO - Chief Executive Officer
CF - Cash FLow
CFO - Chief Financial Officer
COGS - Cost of OODS Sold
CPO - Chief Product Officer
CTO - Chief Technology Officer
D/E - Debt to Equity
DCF - Discounted Cash Flow
Depr. - Depreciation
Dev - Developer
EBIT - Earnings Before Interest and Taxes
EBITDA - Earnings Before Interest, Axes, Depreciation, and Amortization

HR - Human Resources
Inv. - Inventory
k - Thousands of
KPI - Key Performance Indicators
LE - Legal Entity
LFY - Last Fiscal Year
LLM - Large Language Model
m - Millions of
MTD - Month-To-Date
MVP - Minimum Viable Product
NDA - Non-Disclosure Agreement
NFT - Non-Fungible Token
NPV - Net Present Value
OPEX - Operating Expense
P&L - A Profit and Loss (P&L) Statement
PaT - Profit after Tax
PbT - Profit before Tax
PE - Private Equity
PL - Profit and Loss
POC - Proof of Concept
PPE - Property, Plant, and equipment
PV - Present Value
RE - Return on Equity

Sources: Company's Proprietary Information

Disclaimer

The following information and valuation analysis are provided for informational purposes only and do not constitute financial or investment advice. This presentation is based on assumptions, projections, and historical data, which are subject to inherent uncertainties and risks.

Please note that the valuation results presented here are based on the Discounted Cash Flow (DCF) method and various assumptions, including projected cash flows, growth rates, discount rates, and survival rates. These assumptions are subject to change and may not accurately reflect future market conditions or the performance of the business.

The valuation does not guarantee future financial performance or the accuracy of the projections. Actual results may differ materially from those presented in this analysis due to numerous factors, including but not limited to changes in economic conditions, market dynamics, competition, regulatory factors, and unforeseen events.

Investors and stakeholders are advised to conduct their own independent research, seek professional advice, and carefully consider their individual investment objectives, risk tolerance, and financial situation before making any investment decisions. The information provided in this presentation should not be relied upon as the sole basis for making investment decisions.

Furthermore, no representation or warranty, express or implied, is made regarding the accuracy, completeness, reliability, or availability of the information and analysis presented in this presentation. We disclaim any liability for any loss or damage, including but not limited to indirect or consequential loss information provided.

Past performance is not indicative of future results. Any historical financial information included in this presentation is provided for reference purposes only and may not reflect the current financial position or performance of the business.

The valuation presentation is intended solely for the recipient's use and may not be reproduced, redistributed, or disclosed, in whole or in part, without the prior written consent of the company.
If you have any questions or concerns about this presentation or its contents, please contact our office at sdcs or call us at .